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Abstract 
Alzheimer’s disease (AD) is a neurodegenerative disorder related, in part, to the accumulation 
of amyloid-β peptide (Aβ) and especially the Aβ peptide 1-42 (Aβ1-42). The aim of this study 
was to design nanocarriers able to: (i) interact with the Aβ1-42 in the blood and promote its 
elimination through the “sink effect” and (ii) correct the memory defect observed in AD-like 
transgenic mice. To do so, biodegradable, PEGylated nanoparticles were surface-
functionalized with an antibody directed against Aβ1-42. Treatment of AD-like transgenic mice 
with anti-Aβ1-42-functionalized nanoparticles led to: (i) complete correction of the memory 
defect; (ii) significant reduction of the Aβ soluble peptide and its oligomer level in the brain 
and (iii) significant increase of the Aβ levels in plasma. This study represents the first 
example of Aβ1-42 monoclonal antibody-decorated nanoparticle-based therapy against AD 
leading to complete correction of the memory defect in an experimental model of AD. 
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Background 
Alzheimer’s disease (AD) is a neurodegenerative disease with the highest incidence compared 
to other types of dementia.
1, 2
 Mid-2015, the World Health Organization (WHO) estimated 
that AD affected about 36 million people worldwide with an overall economic impact of 
nearly 818 billion USD per year.
3
 Although AD is the focus of intensive research, its 
pathogenesis remains only partially understood and there is still no cure available. 
The two most prominent histopathological hallmarks of AD are extracellular plaques, 
mainly composed of amyloid-β peptide (Aβ) species, and intracellular neurofibrillary tangles 
made of hyperphosphorylated τ protein.4 Several lines of evidence converge towards what is 
known as the “amyloid hypothesis”, according to which the neurofibrillary tangles and the 
associated neurodegeneration are believed to be secondary to the accumulation of Aβ species, 
which would result from the imbalance between the production of Aβ and its clearance from 
the brain.
5
 A considerable amount of knowledge has been accumulated since the first report of 
purification and characterization of Aβ species from the brain tissue of AD patients.6 It is now 
well known that Aβ is produced by the proteolytic cleavage of a larger amyloid precursor 
protein (APP), a constitutively expressed transmembrane glycoprotein with still unclear 
functions.
7, 8
 Under normal conditions, the non-amyloidogenic cleavage of APP by α- and γ-
secretases predominates and generates different non-aggregating fragments.
9
 Alternatively, 
the proteolysis of the APP by the sequential enzymatic actions of β-site amyloid precursor 
protein-cleaving enzyme 1 (BACE1 or β-secretase) and γ-secretase leads to the production of 
Aβ of 37-42 amino acids found in the senile plaques of AD brains.10 Among the different 
species, the Aβ peptide 1-42 (Aβ1-42) is believed to be the most representative and toxic 
species in AD physiopathology because of its high tendency to self-aggregate,
11, 12
 whereas 
the soluble Aβ1-42 oligomer is toxic to neurons.
13, 14
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 Aβ is indeed naturally prone to self-aggregation owing to its enriched sequence in 
hydrophobic residues.
15, 16
 It was recently shown that Aβ oligomers, rather than the 
monomeric form or misfolded Aβ fibrils, are mainly responsible for neurotoxicity.10 
Alongside Aβ oligomerization and deposition, synaptic and neuritic injury occur, as well as 
alterations in neuronal ionic homeostasis, oxidative injury and altered kinase/phosphatase 
activities (responsible for the neurofibrillary tangles), which altogether ultimately lead to 
neuronal dysfunction and cellular death.
17
 
In the past few years, a number of different therapeutic strategies against AD have been 
investigated, including: (i) inhibition/modulation of the secretase activity; (ii) enhancement of 
Aβ clearance from the brain with antibodies or nanoparticulate systems; (iii) decreasing of 
cholesterol levels (given the link between high cholesterol levels and AD incidence); (iv) 
chelation of metallic ions needed for Aβ aggregation and (v) protection of neurons against 
synaptic dysfunction and degeneration.
18-21
 However, current treatments against AD (e.g., 
NMDA receptor antagonist,
22
 AchE inhibitors
23
) are solely palliative and limited to the 
alleviation of symptoms and behavioral disturbances.
24, 25
 Lately, clearance of Aβ from the 
brain was identified as one of the most ambitious strategies for potential treatment of AD.
26
 
The physiological elimination of Aβ1-42 peptide from the brain towards the blood has been 
shown to be promoted by receptors like low-density lipoprotein receptor related protein-1 
(LRP1) and P-glycoprotein (P-gp).  
Nanotechnology and its application to the biomedical field (usually termed 
nanomedicine) hold great hope for the treatment of severe diseases.
27, 28
 So far, only three 
nanoparticulate systems with enhanced affinity for Aβ have been designed to counterbalance 
the deficient Aβ clearance mechanism in vivo: (i) PEGylated liposomes bifunctionalized with 
a peptide deriving from the Apo E receptor-binding domain for blood-brain barrier (BBB) 
targeting and phosphatidic acid for Aβ binding,29, 30 (ii) Apo E3–reconstituted high density 
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lipoprotein (Apo E3–rHDL)31 and (iii) liposomes surface-functionalized by a monoclonal 
anti-A antibody.32 This latter study is very interesting owing to the high affinity and 
specificity of antibodies towards their targets (antigens), reducing off-site binding and 
preventing substantial decrease of the therapeutic efficiency.
33
 However, a proof of efficacy; 
that is the correction of the memory defect, was not investigated and thus, to date, no 
successful in vivo example of antibody-decorated nanoparticle-based therapy against AD 
leading to complete memory recovery has ever been reported, which would represent a crucial 
step forward. 
Among the different classes of materials suitable for drug delivery purposes, 
biodegradable polymer nanoparticles have attracted much attention due to their safety, the 
flexibility offered by macromolecular synthesis methods, the wide range of (co)polymer 
compositions and the possibility to functionalize them for targeting and/or imaging 
purposes.
34
 In this context, poly(alkyl cyanoacrylate) (PACA) nanoparticles represent a well-
established drug delivery platform leading to promising results against different pathologies 
such as cancer or infections
35-38
 and whose degradation is catalyzed in vivo by esterases.
39
 
Importantly, doxorubicin-loaded poly(isohexyl cyanoacrylate) nanoparticles
40
 are currently in 
phase III clinical trial for the treatment of MDR resistant hepatocarcinoma. Moreover, it was 
evidenced that PEGylated nanoparticles of poly[hexadecyl cyanoacrylate-co-
methoxypoly(ethylene glycol) cyanoacrylate] (P(HDCA-co-MePEGCA)) (denoted as NPs in 
this paper) exhibited affinity towards the Aβ1-42 peptide, as observed by surface plasmon 
resonance (SPR), where preferential interaction between PEG chains and Aβ have been 
established.
41
 This affinity was further strongly increased via ‘click chemistry’-based surface-
functionalization by different A targeting ligands such as curcumin derivatives (Curcumin-
NPs) and anti-Aβ1-42 monoclonal antibody (anti-Aβ1-42-NPs, see Figure 1).
42
 SPR experiments 
evidenced an enhanced affinity towards Aβ1-42 monomers (and fibrils) thanks to this surface 
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modification, with KD values of 0.8 µM (and 0.3 µM) and ~700 pM (and ~300 pM) for 
Curcumin-NPs and anti-Aβ1-42-NPs, respectively.
42
 Thus, anti-Aβ1-42-NPs appeared as the 
most promising system to target Aβ peptide to inhibit its aggregation, to favor its clearance 
from the brain and to finally decrease its neurotoxicity. However, the robustness of this 
strategy and therefore its potential as therapy against AD mainly depend on whether these 
nanocarriers can demonstrate improved biological performances in vivo in AD-like animal 
models. 
 
 
Figure 1. Formation of anti-Aβ1-42 monoclonal antibody (mAb)-decorated PEGylated 
P(HDCA-co-MePEGCA) nanoparticles (anti-Aβ1-42-NPs) from biotinylated P(HDCA-co-
MePEGCA) copolymer after nanoprecipitation and incubation with streptavidin (SAav)-anti-
Aβ1-42 mAb. 
 
In this study, we investigated the in vivo pharmacological efficacy of anti-Aβ1-42-NPs in AD-
like transgenic mice and demonstrated that they were able: (i) to bind blood-circulating Aβ1-
42, (ii) to eliminate Aβ1-42 species through nanoparticle clearance pathways and (iii) to 
decrease Aβ1-42 brain levels, likely via the sink effect.
26
 Importantly, AD-like transgenic mice 
treated with anti-Aβ1-42-NPs showed a complete correction of the memory defect, together 
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with a significant reduction of the Aβ soluble peptide and oligomer brain levels, resulting in a 
significant increase of the Aβ levels in plasma. This study represents the first example of Aβ1-
42 monoclonal antibody-decorated nanoparticle-based therapy against AD leading to complete 
correction of the memory defect in an experimental model of AD. 
 
 
Methods 
Materials 
Poly[(hexadecyl cyanoacrylate-co-rhodamine B cyanoacrylate-co-methoxypoly(ethylene 
glycol cyanoacrylate)] (P(HDCA-co-RCA-co-MePEGCA)) and poly[methoxypoly(ethylene 
glycol) cyanoacrylate-co-Biotin-poly(ethylene glycol) cyanoacrylate-co-hexadecyl 
cyanoacrylate] (MePEGCA-co-Bio-PEGCA-co-HDCA) copolymers were obtained following 
previously reported procedures.
42, 43
 Radio-labeled 
14
C-P(HDCA-co-MePEGCA) copolymer 
was prepared at the Commissariat à l’Energie Atomique (Saclay, France) according to 
previously described protocols
44
 and had a specific activity of 5.8 mCi/mg. The Anti-Aβ1-42 
monoclonal Ab was prepared by StabVida (Costa da Caparica, Portugal). Dulbecco’s 
phosphate buffer saline (DPBS) without CaCl2 and MgCl2 and EMB-2 medium were 
purchased from Lonza. Penicillin 10,000 units-streptomycin 10,000 μg.mL-1, trypsin/EDTA 
and chemically defined lipid concentrate were obtained from Invitrogen, Gibco. Pluronic F-
68, hydrocortisone, trypsine/EDTA 1X, human basic fibroblast growth factor (bFGF) cell 
culture tested, glycerol, Tris buffer, sodium dodecyl sulfate (SDS) (≥ 98.5%), Triton X100, 
3',3",5',5"-tetrabromophenolsulfonphthalein (bromophenol blue), 1,4-dithioerythritol (DTE), 
acrylamide (40%), tetramethylethylenediamine (TEMED) (~99%), paraformaldehyde (PFA), 
CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate), thiourea, urea, 
dithiothreitol (DTT), iodocetamide, glycine, Sypro ruby, agarose, Bradford reagent ammoniun 
8 
 
persulfate (APS) (98%), iminothiolane hydrochloride (≥ 98%), streptavidin FITC ( ≥ 5 
units/mg protein), N-hydroxy-succimide (98%), Supedex Prep Grade 200 gel and ascorbic 
acid were purchased from Sigma-Aldrich. Acetone (> 99.95%) was purchased from Carlo 
Erba. Soluene-350 and Hionic-Fluor were purchased from Perkin Elmer.  
 
 
Nanoparticle preparation and characterization 
Fluorescently- and radio-labelled nanoparticles (NPs). The different non-functionalized NPs 
were prepared following previously described protocols from P(HDCA-co-RCA-co-
MePEGCA) or 
14
C-P(HDCA-co-MePEGCA) copolymers.
43, 44
 For biotinylated NPs (Bio-
NPs), 9.5 mg of polymer (either P(HDCA-co-RCA-co-MePEGCA) or 
14
C-P(HDCA-co-
MePEGCA)) and 0.5 mg of P(MePEGCA-co-Bio-PEGCA-co-HDCA) were dissolved in 
acetone (2 mL) and added dropwise to an aqueous solution 0.5% (w/v) of Pluronic F-68 (4 
mL) under vigorous stirring. Acetone was then evaporated under reduced pressure and the 
NPs purified by ultracentrifugation (150,000 g, 1 h, 4 °C, Beckman Coulter). The supernatant 
was discarded and the pellet was resuspended in the appropriate volume of nanopure water to 
reach a final concentration of 2.5 mg.mL
-1
. 
Conjugation of streptavidin FITC with anti-Aβ1-42 mAb. 2.5 µL of iminothiolane 
hydrochloride (2 mg.mL
-1
 in borate buffer 0.16 M pH 8 EDTA 0.1 M) were added to 40 µL of 
streptavidin FITC (2.5 mg.mL
-1
 in borate buffer 0.16 M pH 8 EDTA 0.1 M) and incubated for 
30 min under stirring. In parallel 2.5 µL of N-hydroxysuccimide (1 mg.mL
-1
 in DMF) were 
added to 132.5 µL of anti-Aβ mAb (0.7 mg.mL-1 in DPBS) and incubated for 90 min under 
stirring. The two solutions were purified by Amicon Ultra 0.5 30 KDa filter centrifugation 
(18,000 g, 5 min, room temperature) and then mixed together. The final volume was adjusted 
to 100 µL with PBS, gently stirred for 120 min and then purified by column filtration using 
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Supedex Prep Grade 200 gel. Conjugation was assessed by semi-native polyacrylamide gel 
electrophoresis (PAGE) (Biorad apparatus) (Figure S1) and the conjugation yield was 
quantified by spectrofluorimetry (Perkin Elmer Luminescence Spectrometer). 
Anti-Aβ1-42-decorated NPs (anti-Aβ1-42-NPs). 1 mL of the purified streptavidin FITC-anti-Aβ1-
42 mAb conjugate was incubated with 1 mL of Bio-NPs (radiolabeled or not) for 30 min. Anti-
Aβ1-42-NPs were purified by ultracentrifugation (150,000 g, 1 h, 4°C, Beckman Coulter). The 
supernatant was discarded and the pellet was resuspended in the appropriate volume of 
nanopure water to obtain a final concentration of 2.5 mg.mL
-1
. The amount of anti-Aβ1-42 
mAb on purified nanoparticles was indirectly evaluated by fluorescence quantification of 
streptavidin FITC since the streptavidin FITC:mAb molar ratio is 1:1. 
Nanoparticle characterization. The average diameter (Dz) of the nanoparticles was measured 
by dynamic light scattering (DLS), weighted by intensity, after dilution 1/100 (v/v) in 
nanopure water with a NanoZS from Malvern (173° scattering angle, Orsay, France) at 25 °C. 
The nanoparticle surface charge was determined by ζ-potential measurement at 25 °C after 
dilution with 1 mM NaCl solution applying the Smoluchowski equation and using the same 
apparatus.  
All nanoparticle formulations were stored at 4 °C in the dark. 
 
In vivo pharmacokinetic and biodistribution of the nanoparticles in normal mice 
Animals. 32 NIHS adult male mice between 17 and 27 g (Harlan Laboratories) were used for 
this purpose according to European Union (EEC Council Directive 86/609, OJ L 358,1; 12 
December 1987) laws and policies and in accordance with the Principles of Laboratory 
Animal Care and legislation in force in France (Decree No. 2013-118 of February 1, 2013).  
Animal treatment. Mice were intravenously (IV) injected with radio-labelled anti-Aβ1-42-NPs 
(40 mg/kg). The dose was selected to allow comparisons with previously published results
30
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and according to the Standard Operating Procedures and Guidelines in animal 
experimentation. The animals were sacrificed after different times (5 min, 1 h, 4 h and 8 h) by 
euthanasia with pentobarbital. The blood was withdrawn and further centrifuged (4,500 g, 15 
min, room temperature, 5810 R centrifuge) to collect the plasma while liver, spleen, kidneys 
and brain were collected, weighed, and stored at –80 °C.  
Organ analysis. To quantify the amount of NPs, the different tissues were incubated overnight 
with H2O2 at 50 °C. Then, Soluene-350 was added and the samples were stored for 1 h at 50 
°C. Hionic-Fluor was added and the samples were vortexed for 30 s. After 1 h at room 
temperature, the samples were finally analyzed by scintigraphy (Beckman Coulter L5 6500 
Multi-Purpose Scintillation Center). 
 
In vivo evaluation of the nanoparticles in AD-like transgenic mice 
Animals. 17 Tg2576 14 month-old AD-like transgenic male mice (B6;SJL-
Tg(APPSWE)2576Kha, Taconic Europe) and 9 wild type (WT) age-matched littermates were 
used for anti-A1-42-NPs evaluation. Tg2576 mice carry a transgene coding for the 695-amino 
acid isoform of human Alzheimer Aβ precursor protein carrying the Swedish mutation. All 
animals were single housed in a specific pathogen free facility in standard mouse cages 
containing sawdust with food (2018S Harlan diet) and water ad libitum, under conventional 
laboratory conditions (room temperature: 20 ± 2 °C; humidity: 60%) and a 12/12 h light/dark 
cycle (7:00 am – 7:00 pm). Drug treatment and behavioral tests were all conducted during the 
light cycle. No environmental enrichment was used, since it is well known to improve AD 
mouse pathology.
45, 46
 All procedures involving animals and their care were conducted 
according to European Union (EEC Council Directive 86/609, OJ L 358,1; 12 December 
1987) and Italian (D.L. n.116, G.U. suppl. 40, 18 February 1992) laws and policies and in 
accordance with the United States Department of Agriculture Animal Welfare Act and the 
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National Institutes of Health (Bethesda, MA, USA) policy on Human Care and Use of 
Laboratory Animals. They were reviewed and approved by the Mario Negri Institute Animal 
Care and Use Committee that includes ad hoc members for ethical issues. 
Animal treatment. For novel object recognition tests, all animals (Tg or WT) were IV injected 
with 100 L (40 mg/kg of polymer) of fluorescently-labelled anti-A1-42-NPs (0.8 mg/kg of 
antibody) or PBS as vehicle once every other day for three weeks. To prevent the effect of 
subjective bias, animals were allocated to treatment by an operator not involved in the study 
and animal groups were named with numbers. Mice were treated always at the same time of 
the day (9–11 am), in a specific room inside the animal facility, following a randomized 
order.  
Novel Object Recognition (NOR) test. NOR is a memory test which relies on spontaneous 
animal behavior without the need of stressful elements such as food or water deprivation or 
electric foot shock.
47
 In the NOR mice are introduced into an arena containing two identical 
objects that they can explore freely. Twenty-four hours later mice are reintroduced into the 
arena, containing two different objects one of which previously presented (familiar) and a 
new completely different one (novel). At the end of treatment mice were tested in an open-
square grey arena (40 x 40 cm), 30 cm high, with the floor divided into 25 squares by black 
lines, placed in a specific room dedicated to behavioral analysis and separated from the 
operator’s room. The following objects were used: a black plastic cylinder (4 x 5 cm), a glass 
vial with a white cup (3 x 6 cm) and a metal cube (3 x 5 cm). The task started with a 
habituation trial during which the animals were placed in the empty arena for 5 minutes and 
their movements recorded as the number of line-crossings, which provide an indication of 
both WT and Tg mice motor activity. The next day, mice were again placed in the same arena 
containing two identical objects (familiarization phase). Exploration was recorded in a 10-
minute trial by an investigator blinded to the genotype and treatment. Sniffing, touching and 
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stretching the head toward the object at a distance of not more than 2 cm were scored as 
object investigation. Twenty-four hours later (test phase) mice were again placed in the arena 
containing two objects: one of the objects presented during the familiarization phase (familiar 
object, FAM), and a new, different one (novel object, NOV), and the time spent exploring the 
two objects was recorded for 10 min. Mice were tested following a pre-defined scheme (5 
mice for each treatment group and the remaining mice by following the same scheme) so to 
precisely maintain the 24 h of re-test for each mouse. Results were expressed as % time of 
investigation on objects/10 min or as discrimination index (DI), that is: (seconds spent on 
novel – seconds spent on familiar)/(total time spent on objects). Animals with no memory 
impairment spent longer time investigating the novel object, giving a higher discrimination 
index. 
Brain immunohistochemistry. Tg2576 plaque deposition was examined using the 6E10 
monoclonal anti-Aβ antibody (Covance, CA) following a previously reported procedure.30 
Brain coronal cryostat sections (30 μm; 3 slice/mouse) were incubated for 1 h at RT with 
blocking solutions (10% normal goat serum in PBS) then overnight at 4°C with the primary 
antibodies (1:500). After incubation with the anti-mouse biotinylated secondary antibody 
(1:200; 1h RT, Vector Laboratories) immunostaining was developed using the avidin-biotin 
kit (Vector Laboratories) and diaminobenzidine (Sigma, Italy). Tissue analysis and image 
acquisition were done using an Olympus image analyzer and the Cell-R software.  
Statistical analysis. Data were expressed as mean ± standard error of the mean (SEM). For the 
NOR test, data were analysed by a one-way analysis of variance (ANOVA). In the presence 
of a significant effect of treatment the Tukey’s post-hoc test was applied. A p-value < 0.05 
was considered significant. 
 
Ex vivo experiments after treatment in AD-like transgenic mice 
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Brain homogenate preparation and quantification of Aβ1-42 and Aβ1-40. Brain homogenates 
were prepared as reported elsewhere
30, 48
 with some modifications. Frozen mouse brain 
hemispheres were thawed for ~30 s, weighted and homogenized (1:2 w/v) in ice-cold 
extraction buffer containing 50 mM TRIS-HCl (pH 7.4), 150 mM NaCl, 50 mM EDTA, 1% 
Triton X-100 (TX) and 2% protease inhibitor cocktail (Roche) with a manual tissue 
homogenizer (Eppendorf, Italy). Brain homogenates were centrifuged at 21 000 g, 4 °C for 30 
min and the supernatants, referred to as the Triton-soluble fractions (soluble A), were 
removed with care taken not to disturb the pellet and stored at -80 °C until A dosage. The 
pellets remaining after the TX extract were re-suspended in 70% formic acid (FA) (1:10 w/v), 
homogenized and centrifuged at 100.000 g, 4 °C, 1 h in Beckman TL-100 ultracentrifuge. The 
resulting FA-extracted supernatants, referred to as FA-soluble fraction (insoluble A) were 
neutralized with 1 M TRIS buffer (pH 11) and stored at -80°C until A dosage.  
Levels of Aβ1-40 and Aβ1-42 in each fraction were quantified by sandwich enzyme-
linked immunosorbent assay (ELISA kit, IBL, Germany) following the manufacturer’s 
instruction. The total protein content in each fraction was quantified by bicinchoninic acid 
assay (Sigma-Aldrich, Milano, Italy). All samples were analyzed at least in triplicate. 
Western blot analysis of brain Aβ assemblies. Western blot analysis of A oligomers was 
performed as reported elsewhere
30, 49 
with some modifications. Aliquots of TX-soluble A 
fractions containing 50 µg of total proteins (quantified by bicinchoninic acid assay, Sigma-
Aldrich, Milano, Italy) were combined with NuPAGE® Sample Buffer, heated at 70 °C for 10 
min before electrophoresing on NuPAGE Novex 4–12% Bis-tris gels at 200 V for 35 min 
(Invitrogen corporation, Milano, Italy) and electro-transferred onto nitrocellulose membrane 
(GE Healthcare). The membrane was blocked in 5% skim milk in TRIS buffered saline-
tween-20 (TBS-T) (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 8.0) for 30 min at 
37 °C, incubated with the 6E10 anti-Aβ antibody (1:1000 dilution) in blocking buffer 
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overnight at 4°C. Blot was rinsed in TBS-T and then incubated with secondary antibody (1.5 
h, RT, 1:20 000 dilution), followed by further rinsing. Bands were visualized with enhanced 
chemiluminescence (ECL) Reagent (Amersham, USA) and then imaged using ImageQuant 
LAS4000 (GE Healthcare). Molecular weight of A bands was determined by comparison to 
the SeeBlue®Plus2 Pre-stained Standard (Invitrogen corporation, Milano, Italy). The content 
of soluble A assemblies was quantified by measuring the intensity of the chemiluminescent 
bands using ImageJ Software.  
Quantification of Aβ in plasma. After sacrifice, mice blood was collected from the hearth and 
processed for plasma separation. Levels of Aβ1-40 and Aβ1-42 in plasma were quantified by 
sandwich enzyme-linked immunosorbent assay (Wako Chemicals GmbH, Germany) 
following the manufacture’s instruction. All samples were analyzed at least in triplicate. 
 
Results  
Preparation of anti-Aβ1-42-NPs  
Nanoparticles with high affinity for the Aβ1-42 peptide were produced by coupling an anti-
Aβ1-42 monoclonal antibody at the PEG chain ends of P(HDCA-co-MePEGCA) nanoparticles 
via Bio-SAv ligation.
42
 In particular, the P(MePEGCA-co-Bio-PEGCA-co-HDCA) 
copolymer was nanoprecipitated in water and the resulting Bio-NPs were incubated with a 
streptavidin FITC-anti-Aβ1-42 mAb conjugate to yield anti-Aβ1-42-NPs (see Methods section). 
The nanoparticles presented an average diameter of 125 nm with rather narrow particle size 
distributions (PDI = 0.1–0.2) and negative ζ-potentials (-20 to -30 mV). These characteristics 
did not significantly change during the duration of the experiments, thus showing great 
colloidal stability. To enable accurate tracing during biological evaluations, radio-labelled 
anti-Aβ1-42-NPs were also prepared, simply by blending a small amount of 
14
C-P(HDCA-co-
15 
 
MePEGCA) copolymer with P(MePEGCA-co-Bio-PEGCA-co-HDCA) prior their co-
nanoprecipitation to give 
14
C anti-Aβ1-42-NPs (average diameter = 182 nm, PDI = 0.22). 
 
 
Pharmacokinetics and biodistribution of anti-Aβ1-42-NPs  
To evaluate their biodistribution profile, wild type (WT) mice were intravenously injected 
with 
14
C anti-Aβ1-42-NPs (40 mg/kg) and the radioactivity was quantified at increasing time 
point in blood, liver, spleen, kidneys and brain (Figure 2). The nanoparticles demonstrated 
long blood circulation half-life because of their PEG coating (more than 19% of the injected 
dose/g of organ after 8 h) with preferential accumulation in liver (plateauing at 13% after 1 h), 
spleen (constantly more than 50% after 1 h) and, to a lesser extent, in kidneys (4-7% at 8 h). 
Importantly, although liver accumulation was previously observed for non-functionalized 
P(HDCA-co-PEGCA) NPs,
38
 the high amount accumulating in the spleen seems peculiar for 
14
C anti-Aβ1-42-NPs. The spleen has a blood filtration system presenting tight reticular mesh 
of 200 nm in width.
50
 Consequently, 
14
C anti-Aβ1-42-NPs could be preferentially taken up by 
the spleen due to their average bigger size compared to the non-functionalized NPs, as 
previously described for other NPs.
51 
A low, but detectable amount of 
14
C anti-Aβ1-42-NPs 
was also found in the brain (~0.5%), confirming the ability of these NPs to diffuse into the 
brain tissue to a certain extent.
52, 53
 
 
 
 
16 
 
 
Figure 2. Biodistribution of radio-labelled anti-Aβ1-42-NPs in wild type mice. 
Quantification of 
14
C anti-Aβ1-42-NPs in the main organs at 5 min, 1 h, 4 h and 8 h after 
intravenous injection of 40 mg/kg in wild type mice (n = 4). 
 
Novel object recognition (NOR) test  
To evaluate the effect of anti-Aβ1-42-NPs on memory recovery, AD-like transgenic mice (Tg 
2576) and WT mice were intravenously injected (3 days/week for 3 weeks) with 100 µL of 
PBS buffer (untreated) or anti-Aβ1-42-NPs (40 mg/kg), following by their evaluation by a 
NOR test. NOR is a memory test that relies on spontaneous animal behaviour and has become 
a widely used model for investigating memory alterations.
47
 Figure 3 shows that Tg2576 
animals receiving PBS were unable to discriminate between familiar and novel objects (% 
investigation FAM: 52.8 ± 3.3, NOV: 47.2 ± 3.3; DI:-0.1), thus displaying a significant 
memory impairment compared to WT mice (% investigation FAM: 36.3 ± 3.7, NOV: 63.7 ± 
3.7; DI: 0.27). On the other hand, Tg2576 mice treated with anti-Aβ1-42-NPs significantly 
recovered their long-term recognition memory, near to normal (% investigation FAM: 36.5 ± 
2.4, NOV: 63.5 ± 2.4; DI:0.26). Importantly, neither transgene nor treatment affected motor 
behaviour of mice measured as total number of movements inside the empty arena during the 
17 
 
habituation trial of the NOR test (one-way ANOVA: F2,23 = 1.2; P = 0.3). Altogether, these 
data demonstrated that an acute treatment with anti-Aβ1-42-NPs (40 mg/kg of polymer) 
completely restored memory deficit in Tg2576 mice. Further experiments would be required 
to investigate the effect of lower doses and/or shorter treatments to refine the therapeutic dose. 
 
 
Figure 3. Impact of nanoparticle-based treatments on Tg2576 mouse memory. Memory 
evaluation after PBS or anti-Aβ1-42-NPs (40 mg/kg) administration 3 injections/week for 3 
weeks: (A) time % investigation on the novel vs. the familiar object of WT mice (n = 9) and 
Tg2576 mice (n = 9) at the end of treatment; (B) quantification of discrimination index. 
Histograms are mean ± SEM. One-way ANOVA found a significant effect of treatment: F2,23 
= 8.0, p = 0.002. **p < 0.01 by Tukey’s post-hoc test.  
18 
 
Brain and plasma levels of Aβ 
To elucidate the mechanisms governing the observed in vivo efficacy of anti-Aβ1-42-NPs, 
dosage of Aβ species in brain and plasma of mice was performed. After treatment with anti-
Aβ1-42-NPs, mice were sacrificed and brain hemispheres were analyzed for the soluble and 
insoluble Aβ content by ELISA. The results showed that the treatment did not induce any 
significant reduction of insoluble brain Aβ burden (Figure 4a), whereas a significant reduction 
(-20 %) of the Triton-soluble Aβ1-40 and Aβ1-42 levels (15.40  1.72 and 98.59  9.13 pmols of 
A/mg total proteins, respectively) was detected by comparison with the soluble Aβ1-40 and 
Aβ1-42 levels in mice treated with PBS (21.73  3.38 and 114.07  10.11 pmols of Aβ/mg of 
total proteins, respectively) (Figure 4b). 
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Figure 4. Soluble and insoluble Aβ levels in the brain of Tg2576 mice after treatment 
with anti-Aβ1-42 NPs. (A) Insoluble Aβ1-40 and Aβ1-42 levels in the brain of Tg2576 mice after 
3 weeks’ treatment with anti-Aβ-NPs or PBS. Data (mean ± SD) are expressed as pmol of 
Aβ/mg of total proteins. (B) Triton-soluble Aβ (i.e., oligomers) levels in the brain of Tg2576 
mice are reduced after treatment with anti-Aβ1-42-NPs. Triton-soluble Aβ levels in the brain of 
Tg2576 mice after 3 weeks’ treatment with anti- Aβ1-42 -NPs or PBS. Data (mean ± SD) are 
expressed as a % of change of Aβ levels. p values were calculated by Student’s t test.  
 
 
In parallel, an aliquot of the Triton-soluble Aβ fraction was submitted to SDS-PAGE/WB. 
Representative western blot of brain soluble Aβ probed with 6E10 anti-Aβ mAb and 
visualized by ECL (Figure 5a). An estimation of the Aβ assemblies sorted by molecular 
weight (MW) was performed by quantifying the intensity of the chemiluminescent bands 
20 
 
using the ImageJ Software. It was observed that treatment with anti-Aβ1-42-NPs significantly 
reduced the amount of Aβ oligomers for all analyzed MWs with the highest effect observed 
for oligomers ≤ 49 kDa (Figure 5b). 
 
Figure 5. Amount of Aβ oligomers of different MW in the brain of Tg2576 mice after 
treatment with anti-Aβ-NPs. (A) Representative WB of Aβ oligomers probed with 6E10 
anti-Aβ1-42 mAb and visualized by ECL. (B) Estimation of Aβ assemblies sorted by MW 
present in the brain of Tg2576 treated with PBS taken as reference or with anti-Aβ1-42-NPs 
obtained by quantifying the intensity of the chemiluminescent bands using the ImageJ 
Software. Data (mean ± SD of triplicate experiments) are expressed as % of change of Aβ 
levels. p values were calculated by Student’s t test. 
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After treatment of Tg2576 mice with anti-Aβ1-42-NPs or PBS, blood was also collected from 
the heart and processed for plasma separation. Total levels of Aβ1-40 and Aβ1-42 were 
quantified by ELISA assay. Figure 6 showed that the 3 weeks’ treatment with anti-Aβ1-42-NPs 
induced a significant increase (+ 20%) of the Aβ levels in plasma compared to the mice 
treated with PBS.  
 
 
Figure 6. Aβ levels in plasma of Tg2576 mice after treatment with anti-Aβ1-42-NPs. 
Tg2576 mice treated with PBS or with anti-Aβ1-42-NPs. Data (mean ± SD) are expressed as a 
% of change of Aβ levels. p values were calculated by Student’s t test.  
 
 
Discussion 
Altogether, these data support the hypothesis of a mechanism explaining the therapeutic 
efficacy of anti-Aβ1-42-NPs to reduce soluble forms of A and rescue memory in AD mice. 
The therapeutic effect observed in vivo could be mainly driven by the higher concentration of 
anti-Aβ1-42-NPs detected in the blood than in the brain, likely through the sink effect.
26
 
Nevertheless, we do not exclude the contribution of the NPs found in the brain since low brain 
concentrations of nanomedicines (e.g., 0.1-0.2 %) have shown significant improvement of 
22 
 
neurological and histological phenotype in neurodegenerative disease animal models.
54
 After 
intravenous injection of anti-Aβ1-42-NPs, their surface would be covered by blood-circulating 
Aβ, followed by clearance of the resulting Aβ-coated NPs by classic nanoparticle elimination 
pathways such as phagocytic uptake and hepatic filtration or through kidney excretion.
55
 This 
would result in a global reduction of blood-circulating Aβ, leading to a drastic decrease of its 
aggregation kinetics. Moreover, the peripheral elimination of Aβ peptides would shift the 
blood-BBB equilibrium of the peptide leading to Aβ translocation from the brain to the 
peripheral circulation mediated by receptors like LRP1 or P-gp, in agreement with the so-
called “sink effect”.  
These results demonstrated the beneficial effect of nanoparticles decorated by an Aβ-
targeted antibody on memory recovery in AD-like transgenic animals and supported the great 
potential of anti-Aβ oriented research. They also represent a promising step towards antibody-
decorated nanoparticle-based therapy against AD and all the results that were collected in this 
study were in good agreement with the “sink effect” hypothesis. Also, not only the conception 
of such nanocarriers is rather simple, as it only relied on surface functionalization of 
PEGylated nanoparticles by an anti-Aβ1-42 monoclonal antibody, but the therapeutic 
mechanism (peripheral action in the blood following intravenous injection) also avoids the 
design of complex multifunctional nanoobjects with, for example, specific ligands to cross the 
BBB. 
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